Is a controlled trial of long-term oral anticoagulants in patients with stroke and non-rheumatic atrial fibrillation worthwhile?
A controlled randomised trial large enough to assess the value of anticoagulating stroke patients in atrial fibrillation would be difficult to conduct in the UK and the results would be applicable to only a small proportion of stroke patients. It would be more worthwhile to organise a trial that als...
主要な著者: | Sandercock, P, Warlow, C, Bamford, J, Peto, R, Starkey, I |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
1986
|
類似資料
-
Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
著者:: Turpie AGG
出版事項: (2014-03-01) -
A new era of anticoagulant therapy in the prevention of stroke in non-rheumatic atrial fibrillation
著者:: Andrei Viktorovich Fonyakin, 等
出版事項: (2012-09-01) -
Adherence to oral anticoagulation in ischemic stroke patients with atrial fibrillation
著者:: Paula Tiili, 等
出版事項: (2021-01-01) -
Old and new oral anticoagulants for secondary stroke prevention in atrial fibrillation
著者:: Tommaso Sacquegna, 等
出版事項: (2015-12-01) -
Prevalence of oral anticoagulation in atrial fibrillation
著者:: Eduardo Bartholomay, 等
出版事項: (2014-09-01)